PCI Biotech to present at BIO-Europe
Press release, Lysaker, November 4th, 2015 – PCI Biotech will present at BIO-Europe on Wednesday, November 4th, 2015 at 10:00 a.m. local time at the International Congress Center in Munich, Germany.The presentation “Photochemical internalisation (PCI) – enhancing delivery in oncology” will be held in presentation room 2 (level 0) and the company will be represented by Mr. Gaël L’Hévéder, CBDO. The presentation will be available at PCI Biotech’s webpage under “News”.About BIO-Europe The 21st annual BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking. The event will take place November 2-4, 2015 at the International Congress Center in Munich, Germany.
About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.
The company currently has a bile duct cancer program in phase I/II clinical development. Bile duct cancer is an orphan indication without any approved medicinal products and a high medical need for better local treatments. It is an indication well suited for PCI treatment, with easy light access for intraluminal surface illumination through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI.
The company is also developing PCI as a CTL (Cytotoxic T Lymphocyte) induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs by enhancing the MHC I antigen presentation of antigen presenting cells. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.
The PCI technology is also very well suited for intracellular delivery of nucleic acids, such as RNA therapeutics. By releasing nucleic acid compounds from endosomes where they are trapped following administration, PCI addresses one of the major bottlenecks facing this emerging and exciting field.
PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.
For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429